<?xml version='1.0' encoding='utf-8'?>
<document id="31282592"><sentence text="Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects."><entity charOffset="10-22" id="DDI-PubMed.31282592.s1.e0" text="Itraconazole" /><entity charOffset="26-34" id="DDI-PubMed.31282592.s1.e1" text="Rifampin" /><entity charOffset="38-48" id="DDI-PubMed.31282592.s1.e2" text="Itacitinib" /><pair ddi="false" e1="DDI-PubMed.31282592.s1.e0" e2="DDI-PubMed.31282592.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31282592.s1.e0" e2="DDI-PubMed.31282592.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31282592.s1.e0" e2="DDI-PubMed.31282592.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31282592.s1.e1" e2="DDI-PubMed.31282592.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31282592.s1.e1" e2="DDI-PubMed.31282592.s1.e2" /></sentence><sentence text="Itacitinib is a potent, selective JAK-1 inhibitor currently in phase 3 development for the treatment of acute and chronic graft-versus-host disease (GVHD) in combination with corticosteroids"><entity charOffset="0-10" id="DDI-PubMed.31282592.s2.e0" text="Itacitinib" /><entity charOffset="175-190" id="DDI-PubMed.31282592.s2.e1" text="corticosteroids" /><pair ddi="false" e1="DDI-PubMed.31282592.s2.e0" e2="DDI-PubMed.31282592.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31282592.s2.e0" e2="DDI-PubMed.31282592.s2.e1" /></sentence><sentence text=" Itacitinib is primarily eliminated via metabolism by cytochrome P-450 (CYP)3A4 with minimal renal elimination" /><sentence text=" A drug-drug interaction study was conducted to evaluate the impact of the strong CYP3A inhibitor itraconazole or the strong CYP3A4 inducer rifampin on the pharmacokinetics of itacitinib in healthy volunteers"><entity charOffset="98-110" id="DDI-PubMed.31282592.s4.e0" text="itraconazole" /><entity charOffset="140-148" id="DDI-PubMed.31282592.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.31282592.s4.e0" e2="DDI-PubMed.31282592.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31282592.s4.e0" e2="DDI-PubMed.31282592.s4.e1" /></sentence><sentence text=" In cohort 1, subjects received 200 mg sustained release (SR) tablets of itacitinib on days 1 and 6 and 200 mg itraconazole on days 2-7"><entity charOffset="73-83" id="DDI-PubMed.31282592.s5.e0" text="itacitinib" /><entity charOffset="111-123" id="DDI-PubMed.31282592.s5.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.31282592.s5.e0" e2="DDI-PubMed.31282592.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31282592.s5.e0" e2="DDI-PubMed.31282592.s5.e1" /></sentence><sentence text=" In cohort 2, subjects received 200 mg SR itacitinib on days 1 and 9 and 600 mg rifampin on days 2-9"><entity charOffset="80-88" id="DDI-PubMed.31282592.s6.e0" text="rifampin" /></sentence><sentence text=" Thirty-six subjects were enrolled, 18 in each cohort with 17 completing itacitinib dosing in cohort 1 and 15 completing itacitinib dosing in cohort 2"><entity charOffset="121-131" id="DDI-PubMed.31282592.s7.e0" text="itacitinib" /></sentence><sentence text=" Coadministration of itraconazole with itacitinib resulted in a nearly 5-fold increase in area under the concentration-time curve (AUC0-∞ ) (geometric mean ratio [GMR] 4"><entity charOffset="21-33" id="DDI-PubMed.31282592.s8.e0" text="itraconazole" /><entity charOffset="39-49" id="DDI-PubMed.31282592.s8.e1" text="itacitinib" /><pair ddi="false" e1="DDI-PubMed.31282592.s8.e0" e2="DDI-PubMed.31282592.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31282592.s8.e0" e2="DDI-PubMed.31282592.s8.e1" /></sentence><sentence text="88, 90%Cl 4" /><sentence text="17-5" /><sentence text="72) and an ∼3-fold increase in peak concentration (Cmax ) (GMR 3" /><sentence text="15, 90%Cl 2" /><sentence text="58-3" /><sentence text="54)" /><sentence text=" Coadministration of rifampin with itacitinib resulted in a nearly 80% decrease in AUC0-∞ (GMR 0"><entity charOffset="21-29" id="DDI-PubMed.31282592.s15.e0" text="rifampin" /><entity charOffset="35-45" id="DDI-PubMed.31282592.s15.e1" text="itacitinib" /><pair ddi="false" e1="DDI-PubMed.31282592.s15.e0" e2="DDI-PubMed.31282592.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31282592.s15.e0" e2="DDI-PubMed.31282592.s15.e1" /></sentence><sentence text="208, 90%Cl 0" /><sentence text="173, 0" /><sentence text="249) and Cmax (GMR 0" /><sentence text="231, 90%Cl 0" /><sentence text="195, 0" /><sentence text="274)" /><sentence text=" Results of this study informed the study design of the phase 3 GVHD protocols with regard to coadministration of strong CYP3A inhibitors and CYP3A4 inducers" /><sentence text=" These data combined with phase 3 data will inform final dosing recommendations" /><sentence text="" /></document>